Skip to content

Neural Account of Social Placebo Effect

Neural Account of Social Placebo Effect

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03891459
Enrollment
68
Registered
2019-03-27
Start date
2018-06-27
Completion date
2018-11-05
Last updated
2019-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Control Group, Spray+ Group

Keywords

social placebo effect, fMRI, neural account

Brief summary

The current study aimed to reveal the neural mechanism of social placebo belief formation and belief representation, and also investigated how the brain pattern predict the social behavior performance under placebo manipulation.

Detailed description

Participants were randomly assigned to spray+ group (sprayed with saline but told as oxytocin) and control group (sprayed with saline but told as saline). After 10 min, participants were invited to the resting-state, text viewing task in fMRI scanner. In resting state session, participants with their eyes open and were instructed to attend to a black fixation cross centrally presented on a grey projection screen for 8 min (240TR). The Text viewing task employed a mixed block and even-related fMRI design. Participants were asked to judge whether they could understand the stimuli or not by a button press (1=understand; 2=not understand). Three kinds of stimuli were presented in separate block including oxytocin-function, oxytocin-knowledge, robot related stimuli, each category contained 20 sentences. In each block, the sentence (within one category) was presented pseudo-randomized from 5s to 9s (with mean duration of 7s), then followed by a jittered time interval (interval time = sentence duration - response time; if participants made response within 5s, the sentence would not disappear until its duration reached 5s). There were two sessions with six blocks per session, and there were 5 sentences (trials) per block. The order of blocks and sentences were designed to present in pseudo-random order and were applied to all participants.

Interventions

BEHAVIORALspray+ manipulation

Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);

BEHAVIORALcontrol manipulation

Participants in control group were told they sprayed saline (in fact, it was saline).

Sponsors

Beijing Normal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* All participants had normal or corrected-to-normal vision, and mental healthy.

Exclusion criteria

* Participants who reported no history of neurological, endocrine or psychiatric disorders, who majored in psychology in college or recently participated in any other drug study were not recruited.

Design outcomes

Primary

MeasureTime frameDescription
The brain functional connectivity8 mins, 240 TR in scannerFor functional connectivity estimation, we adopted DLPFC, mPFC and reward related brain regions as the seeds to do whole-brain connectivity analysis. And the conducted two-sample T test to examine whether there would be some differences between spray+ and control groups.
Social brain network properties in resting-state8 mins, 240 TR in scannerFor the network properties, we chose the social brain network as our target and interested network, then estimated the global efficiency within this network.And the conducted two-sample T test to examine whether there would be some differences between spray+ and control groups.
The brain response pattern for the key concepts about oxytocin5.33mins, 160TR in scannerWe estimated the beta response trial by trial for each single concept and then investigated the neural representation of all concepts by using representational similarity analysis (RSA).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026